Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial

OBJECTIVE: Because small increments in levels of endogenous plasma estradiol are associated with higher postmenopausal bone mineral density, we investigated the safety and effectiveness in preventing bone loss of unopposed, very-low-dose transdermal estradiol for postmenopausal women. METHODS: This was a randomized, placebo-controlled, double-blind trial with 2-year follow-up at 9 United States clinical centers. The study population comprised 417 postmenopausal women, aged 60–80 years, with intact uterus and bone mineral density z scores of –2.0 or higher, who were randomly assigned to receive either unopposed transdermal estradiol at 0.014 mg/d (n = 208) or placebo (n = 209). All participants received calcium and vitamin D supplementation. Lumbar spine and total hip bone mineral density change was measured by dual-energy X-ray absorptiometry; endometrial hyperplasia incidence was assessed by endometrial biopsy. RESULTS: Median plasma estradiol level in the estradiol group increased from 4.8 pg/mL at baseline to 8.5 pg/mL at 1 year (P < .001 versus baseline) and to 8.6 pg/mL at 2 years (P < .001 versus baseline) and was unchanged in the placebo group. Lumbar spine bone mineral density increased 2.6% in the estradiol group and 0.6% in the placebo group (between-group difference 2.0%, P < .001). Mean total hip bone mineral density increased 0.4% in the estradiol group and decreased 0.8% in the placebo group (between-group difference 1.2%, P < .001). Osteocalcin levels and bone-specific alkaline phosphatase were lower in the estradiol group than the placebo group (P < .001 each). Endometrial hyperplasia developed in 1 woman in the estradiol group but in none of the placebo group (difference in 2-year rates 0.5%, 95% confidence interval 0–7.3%). CONCLUSION: Postmenopausal treatment with low-dose, unopposed estradiol increased bone mineral density and decreased markers of bone turnover without causing endometrial hyperplasia. LEVEL OF EVIDENCE: I

[1]  J. Gallagher,et al.  Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group. , 1999, American journal of obstetrics and gynecology.

[2]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[3]  S. Cummings,et al.  Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. , 1998, The New England journal of medicine.

[4]  I. Yeh,et al.  Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. , 2001, Fertility and sterility.

[5]  S. Cummings,et al.  Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. , 1998, The Journal of clinical endocrinology and metabolism.

[6]  S. Evans,et al.  Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all post‐menopausal ages , 1996, Clinical endocrinology.

[7]  Olof Johnell,et al.  Hormone replacement therapy and risk of hip fracture: population based case-control study , 1998, BMJ.

[8]  M. Kulldorff,et al.  Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. , 2003, JAMA.

[9]  Susan R. Johnson,et al.  Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1996, JAMA.

[10]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[11]  H. Genant,et al.  Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. , 1997, Archives of internal medicine.

[12]  H. Genant,et al.  Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. , 1992, American journal of obstetrics and gynecology.

[13]  D. Felsenberg,et al.  Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women ☆ ☆☆ , 2001 .

[14]  P. Delmas,et al.  Biochemical Markers of Bone Turnover, Endogenous Hormones and the Risk of Fractures in Postmenopausal Women: The OFELY Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  H. Genant,et al.  Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels , 1997 .

[16]  R. Lindsay,et al.  The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss , 1984, Obstetrics and gynecology.

[17]  H. Genant,et al.  Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy , 1982, Annals of internal medicine.

[18]  Dominique Mottier,et al.  Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[19]  R. Boyd,et al.  Efficacy and Local Tolerance of a Low‐Dose, 7‐Day Matrix Estradiol Transdermal System in the Treatment of Menopausal Vasomotor Symptoms , 1996, Obstetrics and gynecology.

[20]  H. Genant,et al.  Low‐dosage micronized 17‐estradiol prevents bone loss in postmenopausal women , 1992 .

[21]  S. Cummings,et al.  Serum estradiol level and risk of breast cancer during treatment with raloxifene. , 2002, JAMA.

[22]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[23]  S. Cummings,et al.  Endogenous Hormones and the Risk of Hip and Vertebral Fractures Among Older Women , 1999 .

[24]  H. Genant,et al.  Low-dosage micronized 17ß-estradiol prevents bone loss inpostmenopausal women , 1992 .

[25]  R. Lindsay,et al.  Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. , 2002, JAMA.

[26]  G. Bachmann,et al.  Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. , 2001, Fertility and sterility.

[27]  E. Oger,et al.  Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.

[28]  R. Recker,et al.  The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. , 1999, Annals of internal medicine.

[29]  D. Felsenberg,et al.  Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women. , 2001, American journal of obstetrics and gynecology.

[30]  U. Ulmsten,et al.  Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol. , 1997, American journal of obstetrics and gynecology.

[31]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[32]  J. Adachi,et al.  Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.

[33]  S. Weiss,et al.  A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group. , 1999, Obstetrics and gynecology.

[34]  A. Tosteson,et al.  Predictors of Difficulty When Discontinuing Postmenopausal Hormone Therapy , 2003, Obstetrics and gynecology.

[35]  H. Ellman,et al.  Randomised, Controlled Comparison of Transdermal Estradiol with Oral Conjugated Estrogens for the Relief of Hot Flushes , 2000 .

[36]  M. Kulldorff,et al.  The Effect of Low Dose Micronized 17β-Estradiol on Bone Turnover, Sex Hormone Levels, and Side Effects in Older Women: A Randomized, Double Blind, Placebo-Controlled Study1 , 2000 .

[37]  Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1996, JAMA.

[38]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[39]  W. Good,et al.  Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women , 2002, Menopause.

[40]  N. Weiss,et al.  Risk of Endometrial Cancer in Relation to Use of Low‐Dose, Unopposed Estrogens , 1998, Obstetrics and gynecology.

[41]  T. Naessén,et al.  Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. , 2002, American journal of obstetrics and gynecology.

[42]  O. Johnell,et al.  Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. , 1998, BMJ.

[43]  S. Weiss,et al.  A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss , 1999 .

[44]  J. Gallagher,et al.  Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients , 1999 .

[45]  J. Risteli,et al.  Effects of low‐ and conventional‐dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmenopausal women , 1996, European journal of clinical investigation.

[46]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.